echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The four sub-centers of the State Drug Administration are listed

    The four sub-centers of the State Drug Administration are listed

    • Last Update: 2021-03-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    two consecutive days, the State Drug Administration four sub-centers have been listed in Shanghai, Shenzhen. This will help promote the transformation of the Yangtze River Delta pharmaceutical medical device achievements, industry gathering and innovative development, and strengthen the Guangdong, Hong Kong and Macao Dawan District drug medical device supervision, service the Great Bay Area and the national drug medical device regulatory reform and innovation.

    bay area ofOn the morning of December 23, the State Drug Administration, the Guangdong Provincial Government and the Shenzhen Municipal Government held a listing ceremony for the Drug Review and Inspection Dawan Division Center of the State Drug Administration and the Medical Device Technical Review and Inspection Dawan Divisional Center in Futian District, Shenzhen.Li Li, secretary of the Party Group of the State Drug Administration, and Wang Weizhong, deputy secretary of the Guangdong Provincial Party Committee and secretary of the Shenzhen Municipal Committee, jointly unveiled the plaque for the two sub-centers, xu Jinghe, deputy director of the State Drug Administration, Chen Liangxian, vice governor of Guangdong Province, and Chen Rugui, mayor of Shenzhen, attended the listing ceremony and delivered speeches. Yan Jiangxuan, deputy director of the State Drug Administration, presided over the listing ceremony.High standard constructionto build a new height in the development of the pharmaceutical industryThe State Drug Administration Drug Review and Inspection Dawan Division Center and the Medical Device Technical Review and Inspection Dawan Division Center were officially established in Shenzhen, which is a concrete action to implement the spirit of General Secretary Xi Jinping's important speech, and is an important initiative of the State Drug Administration to support the guangdong, Hong Kong and Macao Bay Area, Shenzhen pilot area construction and Shenzhen comprehensive reform pilot. Shenzhen will be under the support of the State Drug Administration and the provincial government, high standards to build two sub-centers, to promote more new technologies, new drugs, new equipment in the Bay Area first test, and strive to build a new height in the development of pharmaceutical medical device industry. At the same time, efforts will be made to build the two sub-centers into a practical platform to promote the high-quality integrated development of Guangdong, Hong Kong and Macao Bay Area, deepen the reform of the drug medical device review and approval system cooperation platform, service pharmaceutical industry innovation and development incubation platform.

    high-quality developmentTo build a first-class international exchange and cooperation platformDawan District Pharmaceutical Medical Devices Technology Review and Inspection Sub-Center listed and launched, will provide national-level technical guidance for the innovation and development of drug medical device industry in Guangdong, Hong Kong and Macao Dawan District, by serving Guangdong, Hong Kong and Macao Dawan District pharmaceutical medical device enterprises and innovation team, will greatly reduce the cost of innovation and entrepreneurship, vigorously promote industrial development, for Guangdong, Hong Kong and Macao Dawan District pharmaceutical medical devices high-quality development into a strong impetus. Guangdong will, as always, do a good job in the two sub-centers of the GreatEr Bay Area of the service guarantee work, under the correct guidance of the State Administration of Market Supervision, the State Drug Administration, the two sub-centers of the Great Bay Area to build a first-class platform for international exchanges and cooperation.At the listing ceremony of the two sub-centers in Dawan District, Xu Jing, deputy director of the State Drug Administration, Ren Xiao tie, deputy secretary-general of the Guangdong Provincial Government, and Huang Min, a member of the Standing Committee of the Shenzhen Municipal Committee and a member of the party group of the municipal government, signed a cooperation agreement on behalf of the three parties. The relevant departments of the State Drug Administration, directly under the unit is mainly responsible for comrades, the provincial market supervision bureau party group secretary, director of the secretary of the party group, the provincial drug regulatory bureau party group secretary, the bureau of the Yangtze River, Shenzhen Municipal Committee Standing Committee, the Secretary-General of the Municipal Committee Gao Self-min, the secretary-general of the municipal government Gao Shengyuan and the relevant departments of the Shenzhen Municipal Government, Futian District Government is mainly responsible for comrades to attend the listing ceremony.

    the Yangtze River DeltaOn December 22, the Yangtze River Delta Sub-Center for Drug Review and Inspection of the State Drug Administration and the Yangtze River Delta Sub-Center for Technical Review and Inspection of Medical Devices were listed in Shanghai.It is reported that the State Drug Administration and the Shanghai Municipal Government, after full consultation, decided to set up two sub-centers in Shanghai, aimed at further deepening the reform of the review and approval system, promote the Yangtze River Delta drug medical device achievements transformation, industry gathering and innovation development, to better meet the people's new expectations for drug safety and innovative research and development.According to the cooperation agreement between the State Drug Administration and the Shanghai Municipal Government, the two sides will strengthen the top-level design, establish a scientific, efficient and professional regional review and inspection system, provide quality services for the research and development innovation of pharmaceutical and medical device enterprises, and build the two sub-centers into practical platforms to promote the development of high-quality integration in the Yangtze River Delta region, deepen the reform of the drug and medical device review and approval system, and serve the incubation platform for the innovation and development of the pharmaceutical industry. (Guangdong Drug Administration, China Food and Drug network)
    )
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.